Cialis: first PDE5 inhibitor licensed for benign prostatic hyperplasia

Tadalafil (Cialis) has been approved for the treatment of benign prostatic hyperplasia (BPH).

Tadalafil (Cialis) provides a new treatment option for the management of benign prostatic hyperplasia | SCIENCE PHOTO LIBRARY
Tadalafil (Cialis) provides a new treatment option for the management of benign prostatic hyperplasia | SCIENCE PHOTO LIBRARY

The phosphodiesterase 5 inhibitor is thought to relieve BPH symptoms by relaxing smooth muscle and increasing blood flow to the bladder, prostate and urethra.

Efficacious from as early as week one

The efficacy and safety of tadalafil in BPH was displayed in four 12-week clinical studies that enrolled over 1,500 men. In each study, treatment with tadalafil 5mg daily improved total International Prostate Symptom score by around two points more than placebo, with improvements being observed as early as week one.

Suitable for BPH with erectile dysfunction

Cialis can be used in patients with BPH who require treatment for erectile dysfunction (ED) as the 5mg once-daily dose is licensed for both indications, provided the patient requires frequent use in ED (at least twice weekly).

View Cialis drug record
 
Further information: Lilly Eli & Co Ltd

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Gluten-free prescribing restricted to bread and mixes

Gluten-free prescribing restricted to bread and mixes

GPs in England are no longer able to prescribe gluten-free...

New vitamin D deficiency thresholds recommended

New vitamin D deficiency thresholds recommended

The National Osteoporosis Society (NOS) has updated...

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors may be linked to a doubling in the...

New MIMS table helps prescribers choose asthma inhalers

New MIMS table helps prescribers choose asthma inhalers

Prescribers can now turn to a handy MIMS comparison...